High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease

Сергеева, Анна; Ono, Yoko; Rios, R N Mary Beth; Molldrem, Jeffrey J.

doi:10.1038/sj.leu.2405104

Cited by 30 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-GM-CSF antibodies may be detected at low concentration in healthy subjects and could participate in the regulation of myeloid cells [25]. Anti-GM-CSF antibodies of IgG, IgA or IgM isotypes have been detected in sera from patients with acute myeloid leukaemia, with their concentration being associated with disease activity [26]. A concentration .19 mg?mL -1 is specific to auto-immune PAP, and a concentration ,10 mg?mL -1 has a good negative predictive value [27].…”

Section: Anti-gm-csf Antibodiesmentioning

confidence: 99%

Pulmonary alveolar proteinosis

Borie¹,

Danel²,

Mp³

et al. 2011

European Respiratory Review

239

258

View full text Add to dashboard Cite

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterised by alveolar accumulation of surfactant. It may result from mutations in surfactant proteins or granulocyte macrophage-colony stimulating factor (GM-CSF) receptor genes, it may be secondary to toxic inhalation or haematological disorders, or it may be auto-immune, with anti-GM-CSF antibodies blocking activation of alveolar macrophages. Auto-immune alveolar proteinosis is the most frequent form of PAP, representing 90% of cases. Although not specific, high-resolution computed tomography shows a characteristic ''crazy paving'' pattern. In most cases, bronchoalveolar lavage findings establish the diagnosis. Whole lung lavage is the most effective therapy, especially for auto-immune disease. Novel therapies targeting alveolar macrophages (recombinant GM-CSF therapy) or anti-GM-CSF antibodies (rituximab and plasmapheresis) are being investigated. Our knowledge of the pathophysiology of PAP has improved in the past 20 yrs, but therapy for PAP still needs improvement.

show abstract

Section: Anti-gm-csf Antibodiesmentioning

confidence: 99%

Pulmonary alveolar proteinosis

Borie¹,

Danel²,

Mp³

et al. 2011

European Respiratory Review

239

258

View full text Add to dashboard Cite

show abstract

“…Anti-GM-CSF antibodies may be detected at low concentration in healthy subjects and could participate to the regulation of myeloid cells [ 21 ]. Anti-GM-CSF antibodies of IgG, IgA or IgM isotypes have been detected in sera from patients with acute leukemia, their concentration being associated with disease activity [ 22 ]. A concentration greater than 19 μg/ml is specifi c to autoimmune PAP, and a concentration lower than 10 μg/ml has a good negative predictive value [ 23 ].…”

Section: Anti-gm-csf Antibodiesmentioning

confidence: 98%

Pulmonary Alveolar Proteinosis

Borie¹,

Pradère²,

Danel³

et al. 2014

Orphan Lung Diseases

View full text Add to dashboard Cite

“…Unfortunately, this approach cannot be applied generally to all PAP forms and disease. However, autoimmune PAP and other forms of secondary PAP, namely those associated with malignancies and already receiving GM-CSF priming, and in which autoantibodies against this exogenous therapy may actually be responsible for PAP development can benefit from GM-CSF also for alleviation of the pulmonary impairment [46].…”

Section: Gm-csf Pathway Correction In Pulmonary Alveolar Proteinosismentioning

confidence: 99%